UP­DAT­ED: Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

2 days ago
R&D
Regulatory

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

2 days ago
People

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

2 days ago
Pharma
R&D

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

2 days ago
People

Glen­mark launch­es Re­mogliflozin com­bo in In­dia; Gene­Cen­tric Ther­a­peu­tics buys Se­lect Im­munoGenomics

2 days ago
Protocols

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

2 days ago
R&D

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

2 days ago
IPOs

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

3 days ago
R&D

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

3 days ago
R&D

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

3 days ago
Pharma

EMA and FDA his­tor­i­cal­ly agree on just about every new drug ap­proval, but is that slow­ly chang­ing?

3 days ago
Regulatory

Health­i­er, longer lifes­pans will be a re­al­i­ty soon­er than you think, Ju­ve­nes­cence promis­es as it clos­es $100M round

3 days ago
Venture

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

5 days ago
R&D

UP­DAT­ED: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

5 days ago
Pharma
Regulatory

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

5 days ago
Pharma

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

5 days ago
Pharma

The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

6 days ago
R&D

Bain's Or­ly Mis­han joins Pfiz­er's neu­ro spin­out Cerev­el; On­colyt­ic virus biotech taps Sil­la­Jen ex­ec He­le­na Chaye as CEO

6 days ago
Peer Review

A bud­get biotech you like­ly nev­er heard about is set­ting a course for Wall Street with some mod­est am­bi­tions

6 days ago
IPOs

Watch out Bay­er, Roche is com­ing for you with a dis­count price ri­val to the tu­mor ag­nos­tic drug you got from Loxo

6 days ago
R&D

Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

6 days ago
People
Pharma

Soar­ing De­ci­phera cap­i­tal­izes on pos­i­tive tri­al with $400M of­fer­ing; Spring­Work hires ex-For­est Labs CFO

6 days ago
Protocols

Re­gen­eron puts fin­ish­ing touch­es on $800M ex­pan­sion project close to home

6 days ago
R&D

A PARP suc­ces­sor? Michi­gan aca­d­e­m­ic team touts po­ten­tial of an ag­ing — but still ex­per­i­men­tal — As­traZeneca drug in DNA dam­age re­pair

6 days ago
R&D
First page Previous page 12345 Next page Last page